Finerenone in the management of diabetes kidney disease
De, Parijat Khine, May T Frankel, Andrew Goldet, Gabrielle Banerjee, Debasish Montero, Rosa M Chowdhury, Tahseen A Fogarty, Damien Karalliedde, Janaka Mallik, Ritwika
De, Parijat
Khine, May T
Frankel, Andrew
Goldet, Gabrielle
Banerjee, Debasish
Montero, Rosa M
Chowdhury, Tahseen A
Fogarty, Damien
Karalliedde, Janaka
Mallik, Ritwika
Affiliation
Sandwell & West Birmingham NHS Trust; Imperial College Healthcare NHS Trust; St George's Hospitals NHS Foundation Trust; Barts Health NHS Trust; Belfast Health and Social Care Trust; King's College London; Guy's and St Thomas NHS Foundation Trust; University College London Hospitals NHS Foundation Trust; University College London; Epsom and St Helier University Hospitals NHS Trust; East and North Herts NHS Trust; Swansea University; University Hospitals Birmingham NHS Foundation Trust
Other Contributors
Publication date
2025-02-08
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular disease. Slowing progression of kidney disease and reducing cardiovascular events can be achieved by a number of means including the targeting of blood pressure and the use of specific classes of drugs The use of Renin Angiotensin Aldosterone System (RAAS) blockade is effective in preventing or slowing progression of DKD and reducing cardiovascular events in people with type 2 diabetes, albeit differently according to the stage of DKD. However, emerging therapy such as non-steroidal selective mineralocorticoid antagonists (finerenone) is proven to lower blood pressure and further reduce the risk of progression of DKD and cardiovascular disease in people with type 2 diabetes. This consensus reviews current evidence and make recommendations for the use of finerenone in the management of diabetes kidney disease in the UK.
Citation
De P, Khine MT, Frankel A, Goldet G, Banerjee D, Montero RM, Chowdhury TA, Fogarty D, Karalliedde J, Mallik R, Patel DC, Wahba M, Winocour P, Zac-Varghese S, Bain S, Sharif A, Bellary S, Dasgupta I. Finerenone in the management of diabetes kidney disease. BMC Nephrol. 2025 Feb 8;26(1):63. doi: 10.1186/s12882-025-03985-9.
Type
Article